DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rejinold, Sanoj N. | ko |
dc.contributor.author | Yoo, Jisang | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.contributor.author | Kim, Yeu-Chun | ko |
dc.date.accessioned | 2018-12-20T08:06:24Z | - |
dc.date.available | 2018-12-20T08:06:24Z | - |
dc.date.created | 2018-12-14 | - |
dc.date.created | 2018-12-14 | - |
dc.date.created | 2018-12-14 | - |
dc.date.created | 2018-12-14 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.citation | ACS APPLIED MATERIALS & INTERFACES, v.10, no.34, pp.28458 - 28470 | - |
dc.identifier.issn | 1944-8244 | - |
dc.identifier.uri | http://hdl.handle.net/10203/248768 | - |
dc.description.abstract | Curcumin (CRC) has been widely used as a therapeutic agent for various drug delivery applications. In this work, we focused on the applicability of CRC as a nanodrug delivery agent for doxorubicin hydrochloride (DOX) (commercially known as Adriamycin) coated with poly(ethylene glycol) (PEG) as an effective therapeutic strategy against multidrug-resistant cancer cells. The developed PEG-coated CRC/DOX nanoparticles (NPs) (PEG-CRC/DOX NPs) were well localized within the resistant cancer cells inducing apoptosis confirmed by flow cytometry and DNA fragmentation assays. The PEG-CRC/DOX NPs suppressed the major efflux proteins in DOX-resistant cancer cells. The in vivo biodistribution studies on HCT-8/DOX-resistant tumor xenograft showed improved bioavailability of the PEG-CRC/DOX NPs, and thereby suppressed tumor growth significantly compared to the other samples. This study clearly shows that curcumin nanoparticles could deliver DOX efficiently into the multidrug-resistant cancer cells to have potential therapeutic benefits. © 2018 American Chemical Society. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Curcumin as a Novel Nanocarrier System for Doxorubicin Delivery to MDR Cancer Cells: In Vitro and in Vivo Evaluation | - |
dc.type | Article | - |
dc.identifier.wosid | 000443654600023 | - |
dc.identifier.scopusid | 2-s2.0-85052812745 | - |
dc.type.rims | ART | - |
dc.citation.volume | 10 | - |
dc.citation.issue | 34 | - |
dc.citation.beginningpage | 28458 | - |
dc.citation.endingpage | 28470 | - |
dc.citation.publicationname | ACS APPLIED MATERIALS & INTERFACES | - |
dc.identifier.doi | 10.1021/acsami.8b10426 | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.localauthor | Kim, Yeu-Chun | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | MDR | - |
dc.subject.keywordAuthor | p-glycoprotein | - |
dc.subject.keywordAuthor | curcumin | - |
dc.subject.keywordAuthor | doxorubicin | - |
dc.subject.keywordAuthor | In vivo tumor suppression | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN EXPRESSION | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | CO-DELIVERY | - |
dc.subject.keywordPlus | PENETRATING PEPTIDE | - |
dc.subject.keywordPlus | DRUG NANOCRYSTALS | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | ADRIAMYCIN | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | THERAPY | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.